Literature DB >> 21807905

Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.

Takeshi Miyata1, Tetsuya Harakuni, Takafumi Tsuboi, Jetsumon Sattabongkot, Ayumu Ikehara, Mayumi Tachibana, Motomi Torii, Goro Matsuzaki, Takeshi Arakawa.   

Abstract

The creation of subunit vaccines to prevent malaria infection has been hampered by the intrinsically weak immunogenicity of the recombinant antigens. We have developed a novel strategy to increase immune responses by creating genetic fusion proteins to target specific antigen-presenting cells (APCs). The fusion complex was composed of three physically linked molecular entities: (i) a vaccine antigen, (ii) a multimeric α-helical coiled-coil core, and (iii) an APC-targeting ligand linked to the core via a flexible linker. The vaccine efficacy of the tricomponent complex was evaluated using an ookinete surface protein of Plasmodium vivax, Pvs25, and merozoite surface protein-1 of Plasmodium yoelii. Immunization of mice with the tricomponent complex induced a robust antibody response and conferred substantial levels of P. vivax transmission blockade as evaluated by a membrane feed assay, as well as protection from lethal P. yoelii infection. The observed effect was strongly dependent on the presence of all three components physically integrated as a fusion complex. This system, designated the tricomponent immunopotentiating system (TIPS), onto which any recombinant protein antigens or nonproteinaceous substances could be loaded, may be a promising strategy for devising subunit vaccines or adjuvants against various infectious diseases, including malaria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807905      PMCID: PMC3187242          DOI: 10.1128/IAI.05214-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

Review 1.  Molecular mechanisms of B cell antigen receptor trafficking.

Authors:  Marcus R Clark; Don Massenburg; Miao Zhang; Karyn Siemasko
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

Review 2.  The structure of alpha-helical coiled coils.

Authors:  Andrei N Lupas; Markus Gruber
Journal:  Adv Protein Chem       Date:  2005

3.  Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration.

Authors:  Elke Scandella; Katja Fink; Tobias Junt; Beatrice M Senn; Evelyn Lattmann; Reinhold Förster; Hans Hengartner; Burkhard Ludewig
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

Review 4.  The who, how and where of antigen presentation to B cells.

Authors:  Facundo D Batista; Naomi E Harwood
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

5.  Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.

Authors:  L C Agren; L Ekman; B Löwenadler; N Y Lycke
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

6.  Increased expression of I-region-associated antigen (Ia) on B cells after cross-linking of surface immunoglobulin.

Authors:  J J Mond; E Seghal; J Kung; F D Finkelman
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.

Authors:  H Hisaeda; W E Collins; A Saul; A W Stowers
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

Review 8.  B-cell antigen-receptor signalling in lymphocyte development.

Authors:  Leo D Wang; Marcus R Clark
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

9.  The thrombospondin-like chains of cartilage oligomeric matrix protein are assembled by a five-stranded alpha-helical bundle between residues 20 and 83.

Authors:  V P Efimov; A Lustig; J Engel
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

Review 10.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Authors:  Nathalie Garçon; Patrick Chomez; Marcelle Van Mechelen
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

View more
  5 in total

1.  Identification of the Babesia-responsive leucine-rich repeat domain-containing protein from the hard tick Haemaphysalis longicornis.

Authors:  Hiroki Maeda; Koshi Kurisu; Takeshi Miyata; Kodai Kusakisako; Remil Linggatong Galay; Talactac Melbourne Rio; Masami Mochizuki; Kozo Fujisaki; Tetsuya Tanaka
Journal:  Parasitol Res       Date:  2015-02-19       Impact factor: 2.289

2.  Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potent transmission-blocking immunity.

Authors:  Takeshi Arakawa; Takafumi Tsuboi; Jetsumon Sattabongkot; Kozue Sakao; Motomi Torii; Takeshi Miyata
Journal:  Clin Vaccine Immunol       Date:  2014-02-12

Review 3.  Particle-based platforms for malaria vaccines.

Authors:  Yimin Wu; David L Narum; Sylvain Fleury; Gary Jennings; Anjali Yadava
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

4.  Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.

Authors:  Akitsu Masuda; Jae Man Lee; Takeshi Miyata; Hiroaki Mon; Keita Sato; Kosuke Oyama; Yasuteru Sakurai; Jiro Yasuda; Daisuke Takahashi; Tadashi Ueda; Yuri Kato; Motohiro Nishida; Noriko Karasaki; Kohei Kakino; Takeru Ebihara; Takumi Nagasato; Masato Hino; Ayaka Nakashima; Kengo Suzuki; Yoshino Tonooka; Miyu Tanaka; Takato Moriyama; Hirokazu Nakatake; Ryosuke Fujita; Takahiro Kusakabe
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

5.  A Three Component Synthetic Vaccine Containing a β-Mannan T-Cell Peptide Epitope and a β-Glucan Dendritic Cell Ligand.

Authors:  David R Bundle; Eugenia Paszkiewicz; Hassan R H Elsaidi; Satadru Sekhar Mandal; Susmita Sarkar
Journal:  Molecules       Date:  2018-08-06       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.